Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Frank Schippers"'
Autor:
Jie Zhou, Laura Curd, Lauren R. L. Lohmer, Natalie Delpratt, Joachim Ossig, Frank Schippers, Thomas Stoehr, Virginia D. Schmith
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 4, Pp 1554-1565 (2021)
ABSTRACT The clinical effects of remimazolam (an investigational, ultra‐short acting benzodiazepine being studied in procedural sedation) were measured using the Modified Observer’s Assessment of Awareness/Sedation Scale (MOAA/S). The objective o
Externí odkaz:
https://doaj.org/article/8823091b34104d6087cd60203d9089d8
Autor:
Jie Zhou, Laura Curd, Lauren L. Lohmer, Joachim Ossig, Frank Schippers, Thomas Stoehr, Virginia Schmith
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 1, Pp 326-334 (2021)
Remimazolam is an ultra‐short acting benzodiazepine under development for procedural sedation and general anesthesia. Population pharmacokinetic analysis (PopPK) was conducted for remimazolam with arterial and venous samples previously, but results
Externí odkaz:
https://doaj.org/article/d4c0e8a70c674f4d93ac11f56122c405
Publikováno v:
Endoscopy International Open, Vol 10, Iss 04, Pp E378-E385 (2022)
Background and study aims Remimazolam is an ultra-short acting, fast onset/fast offset benzodiazepine for intravenous use in procedural sedation, general anesthesia, and Intensive Care Unit sedation. The aim of this work was to compare the efficacy o
Externí odkaz:
https://doaj.org/article/110d0401bf814a8e889e84a347ce7675
Autor:
Marija Pesic, Thomas Stöhr, Joachim Ossig, Keith Borkett, Martin Donsbach, Van-Anh Dao, Lynn Webster, Frank Schippers
Publikováno v:
Drugs in R&D, Vol 20, Iss 3, Pp 267-277 (2020)
Abstract Background and Objectives Remimazolam is a new ultra-short-acting benzodiazepine currently being developed for intravenous use in procedural sedation, general anaesthesia, and intensive care unit sedation. Benzodiazepines represent a drug cl
Externí odkaz:
https://doaj.org/article/1d7e4135fdc34fe2a7679e3bb117e9d9
Autor:
Thomas Stoehr, Frank Schippers, Laura Curd, Natalie Delpratt, Virginia D. Schmith, Jie Zhou, Lauren R. L. Lohmer, Joachim Ossig
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 4, Pp 1554-1565 (2021)
Clinical and Translational Science
Clinical and Translational Science
The clinical effects of remimazolam (an investigational, ultra‐short acting benzodiazepine being studied in procedural sedation) were measured using the Modified Observer’s Assessment of Awareness/Sedation Scale (MOAA/S). The objective of this an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12ee97245f9f1720c3f7e77e09269133
https://doaj.org/article/8823091b34104d6087cd60203d9089d8
https://doaj.org/article/8823091b34104d6087cd60203d9089d8
Autor:
Lauren R. L. Lohmer, Frank Schippers, Thomas Stoehr, Joachim Ossig, Virginia D. Schmith, Jie Zhou, Laura Curd
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 14, Iss 1, Pp 326-334 (2021)
Clinical and Translational Science, Vol 14, Iss 1, Pp 326-334 (2021)
Remimazolam is an ultra-short acting benzodiazepine under development for procedural sedation and general anesthesia. Population pharmacokinetic analysis (PopPK) was conducted for remimazolam with arterial and venous samples previously, but results w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72c3dff5a183ed5662ceeff54c7f8908
https://doi.org/10.1111/cts.12875
https://doi.org/10.1111/cts.12875
Autor:
Lynn R. Webster, Thomas Stohr, Martin Donsbach, Frank Schippers, Keith Borkett, Joachim Ossig, Marija Pesic, Van-Anh Dao
Publikováno v:
Drugs in R&D, Vol 20, Iss 3, Pp 267-277 (2020)
Drugs in R&D
Drugs in R&D
Background and Objectives Remimazolam is a new ultra-short-acting benzodiazepine currently being developed for intravenous use in procedural sedation, general anaesthesia, and intensive care unit sedation. Benzodiazepines represent a drug class assoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0207e8c27b0408874728bf10f48db05e
https://doaj.org/article/1d7e4135fdc34fe2a7679e3bb117e9d9
https://doaj.org/article/1d7e4135fdc34fe2a7679e3bb117e9d9
Autor:
Lynn R. Webster, Thomas Stoehr, Marija Pesic, Robert Saunders, Frank Schippers, Shawn L. Searle, Keith Borkett
Publikováno v:
Journal of Clinical Pharmacology
Remimazolam (RMZ) is a new and ultra‐fast‐acting, short‐duration intravenous benzodiazepine, a drug class associated with abuse potential. This trial was designed to compare the abuse potential of remimazolam with placebo and midazolam (MDZ), a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37166b7d888077ffa4139d1445189160
https://doi.org/10.1002/jcph.1614
https://doi.org/10.1002/jcph.1614
Publikováno v:
British Journal of Clinical Pharmacology
Aims Remimazolam is a new, ultra‐short‐acting benzodiazepine developed for intravenous (IV) use during procedural sedation and in general anaesthesia. Two trials were conducted to characterize its effects on cardiac repolarization. Methods A thor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7707ef57d7bcb3b4173817479e0e05e1
http://europepmc.org/articles/PMC7373701
http://europepmc.org/articles/PMC7373701
Publikováno v:
Journal of Clinical Pharmacology
Remimazolam is an ultra‐short‐acting benzodiazepine being investigated for induction and maintenance of general anesthesia and for procedural sedation. This dose‐response analysis of 4 phase 2‐3 studies evaluated covariates that may impact th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::843339e9253d31e5b3090dd2d27da6fa
https://doi.org/10.1002/jcph.1552
https://doi.org/10.1002/jcph.1552